Austar Lifesciences (HKG:6118) expects an attributable profit of between 23 million yuan and 25 million yuan for the six months ended June 30, up from 5.9 million yuan a year prior, a Thursday Hong Kong bourse filing said.
The technology-based pharmaceutical engineering solution provider attributed the upbeat forecast to efficiency enhancement, optimized administrative and R&D expenditures, and a rise in other gains.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments